Modeling acute graft-versus-host disease (aGVHD) in murine bone marrow transplantation (BMT) models with MHC disparity.
Scheurer J, Leithäuser F, Debatin KM, Strauss G.
Methods Cell Biol. 2022;168:19-39. doi: 10.1016/bs.mcb.2021.12.007. Epub 2022 Jan 10.
Donor peritoneal-derived cells can attenuate graft-versus-host disease after MHC-incompatible bone marrow transplantation in mice.
Liu Z, Zeng Q, Chen X, He C, Wang F, Liu T.
Int Immunopharmacol. 2022 Nov;112:109296. doi: 10.1016/j.intimp.2022.109296. Epub 2022 Oct 2.
Evaluation of Immunosuppression Levels and Risk of Graft-Versus-Host Disease in Allogeneic Blood or Marrow Transplantation With Post-Transplantation Cyclophosphamide.
Lee JJ, Norman H, Ziggas JE, Bolaños-Meade J, Porter TJ.
Transplant Cell Ther. 2025 Jun;31(6):363.e1-363.e11. doi: 10.1016/j.jtct.2025.02.024. Epub 2025 Mar 3.
Treatment of acute and chronic graft-versus-host disease with extracorporeal photopheresis: Update of best practice recommendations from Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO).
Colpo A, Marchetti M, Bianco I, Cruciani F, Ipsevich F, Montanari M, Stanghellini MTL; Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO).
Transfus Apher Sci. 2024 Oct;63(5):103990. doi: 10.1016/j.transci.2024.103990. Epub 2024 Aug 13.
Hepatobiliary disease after bone marrow transplant.
Dezan MGF, Cavalcante LN, Cotrim HP, Lyra AC.
Expert Rev Gastroenterol Hepatol. 2023 Feb;17(2):129-143. doi: 10.1080/17474124.2023.2169671. Epub 2023 Feb 2.
Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
Lu SX, Kappel LW, Charbonneau-Allard AM, Atallah R, Holland AM, Turbide C, Hubbard VM, Rotolo JA, Smith M, Suh D, King C, Rao UK, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan O, Blumberg RS, Macian F, Holmes KV, Beauchemin N, van den Brink MR.
PLoS One. 2011;6(7):e21611. doi: 10.1371/journal.pone.0021611. Epub 2011 Jul 6.
Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide.
McCurdy SR, Kanakry CG, Tsai HL, Gojo I, Smith BD, Gladstone DE, Bolaños-Meade J, Borrello I, Matsui WH, Swinnen LJ, Huff CA, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.
Biol Blood Marrow Transplant. 2019 Jun;25(6):1128-1135. doi: 10.1016/j.bbmt.2018.12.767. Epub 2018 Dec 30.
Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.
Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L.
Semin Hematol. 2016 Apr;53(2):90-7. doi: 10.1053/j.seminhematol.2016.01.005. Epub 2016 Jan 15.
Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
Mehta RS, Peffault de Latour R, DeFor TE, Robin M, Lazaryan A, Xhaard A, Bejanyan N, de Fontbrune FS, Arora M, Brunstein CG, Blazar BR, Weisdorf DJ, MacMillan ML, Socie G, Holtan SG.
Haematologica. 2016 Jun;101(6):764-72. doi: 10.3324/haematol.2015.138990. Epub 2016 Apr 1.
Management of graft-versus-host disease in paediatric bone marrow transplant recipients.
Zecca M, Locatelli F.
Paediatr Drugs. 2000 Jan-Feb;2(1):29-55. doi: 10.2165/00148581-200002010-00004.
